# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person* LEPORE PATRICK G					2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302					3. Date of Earliest Transaction (Month/Day/Year) 08/16/2019						Offic	er (give title belo	ow)	Other (specify b	elow)		
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
	BEDMINSTER, NJ 07921 (City) (State) (Zip)					Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		Date	Date (Month/Day/Year) a				(Instr. 8)		on 4. Securities Acquired (A or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Fol Reported Transaction(s)		Following	6. Ownership Form:	Beneficial		
					(Monti	h/Day/Yea	ar)	Code	V	Amount	(A) or (D)	Price	(Instr. 3	(Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common \$0.0001	Stock, pa per share	r value	08/16	5/2019				P		100,000	) I A	\$ 0.718	5 200,00	00		D	
				Table II -					th uired	ontained i e form di	n this fo splays a of, or Be	orm ar a curre eneficia	e not req ently valid	ction of inf uired to res I OMB con	spond unle	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		E ay/Year) ai	3A. Deemed Execution Da	4.		on Non S	5.		and Expiration Date (Month/Day/Year) L S		7. T Am Und Sec	Fitle and count of derlying curities str. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form of Derivativ Security: Direct (D or Indirect	Beneficia Ownersh (Instr. 4)
										Date exercisable	Expiration Date	on Titl	Amount or Number of				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LEPORE PATRICK G C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER, NJ 07921	X					

# **Signatures**

/s/ Jerome D. Jabbour, attorney-in fact for Patrick G. LePore	08/20/2019		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.